Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections

Yong Kyun Kim¹, Jin Ah Jung², Hyang-Ki Choi², In-Gyu Bae³, Won Suk Choi³, Jian Hur⁵, Sung Joon Jin⁶, Shin-Woo Kim⁷, Ki Tae Kwon⁸, Sang-Rok Lee⁹, Jae-Gook Shin⁹, Sungmin Kim⁴, and Pharmacokinetics-Pharmacodynamics of Antibiotics Working Group under Korean Society for Chemotherapy

¹Division of Infectious Diseases, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine; ²Department of Clinical Pharmacology, Inje University College of Medicine, Busan; ³Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju; ⁴Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Ansan; ⁵Department of Internal Medicine, Yeungnam University Medical Center, Daegu; ⁶Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; ⁷Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Hospital, Daegu; ⁸Department of Internal Medicine, Daegu Fatima Hospital, Daegu; ⁹Division of Allergy and Infectious Diseases, Department of Internal Medicine, Cheongju St. Mary’s Hospital, Cheongju, Korea

Background: For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients’ characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections.

Materials and Methods: At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CLcr) ≤50 mL/min or CLcr >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of \( P <0.05 \) for selection and \( P <0.01 \) for elimination.

Results: Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as \( CL = 2.9 + 4.03 \times CL_{cr}/47 \) for piperacillin and \( CL = 1.76 + 4.81 \times CL_{cr}/47 \) for tazobactam. V1 was defined as \( V1 = 19.5 \times \text{weight}/60 \) for piperacillin and \( V1 = 22.6 \times \text{weight}/60 \) for tazobactam.

Conclusion: The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance.

Key Words: Piperacillin; Tazobactam; Race; Population pharmacokinetics; Clearance

Received: April 20, 2016 Revised: June 30, 2016 Accepted: July 16, 2016

Corresponding Author: Sungmin Kim, MD
Division of Infectious Diseases, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeundae-daero, Haeundae-gu, Busan 48108, Korea.
Tel: +82-51-797-0320, Fax: +82-51-797-3229
E-mail: smkimkor@yahoo.com

* Both contributed equally to this article as co-first authors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyrights © 2016 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy

www.icjournal.org
Introduction

Owing to its broad antibacterial spectrum and documented efficacy, piperacillin/tazobactam (TZP), when indicated based on the severity of infection, has been prescribed widely in both community and healthcare settings [1, 2]. Several recent studies regarding its efficacy for treating infections caused by extended-spectrum β-lactamase (ESBL)-producing organisms highlight the usefulness and importance of TZP as broad-spectrum antibiotics in the treatment of serious infections [3, 4].

For a rapid antibacterial effect and the restriction of resistance development, dosing of TZP is important. Usually, the initial recommended dose of TZP is categorized into three groups based on the glomerular filtration rate (GFR), and the maintenance dose is recommended to achieve maximized free time above the minimum inhibitory concentration (Ft>MIC) [5-9]. However, the initial dose could be either too high or low for some patients, depending on the patient characteristics, such as renal dysfunction, and critical illness status. In addition, the maintenance dose should be adjusted appropriately using therapeutic drug monitoring (TDM) to improve outcomes, particularly in critically ill patients [10]. Therefore, dosing regimens of TZP need to be individualized and monitored by TDM using data from patient population pharmacokinetics.

Race is one of the important individual characteristics and ethnic differences may affect drug pharmacokinetics or pharmacodynamics [11, 12]. Several previous studies evaluated the population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam in Korean patients who had burn injuries and renal failure [13, 14]. However, to our knowledge, no studies have evaluated the population pharmacokinetics in hospitalized Korean patients with infections.

Our institution has performed studies to develop and validate the individualized dosing of important antibiotics in Korean patients [15]. There are fundamental differences in the fat distribution, metabolism, drug transport genetics, and antibiotic clearance (CL) between western and Korean patients. Therefore, in the present study, we aimed to determine the population pharmacokinetics and CL equations of TZP in Korean patients with infections, which could help to develop individualized dosing of TZP based on an understanding of its inter-ethnic differences.

Materials and Methods

1. Study population

From April 2013 to April 2015, patients with acute infections aged over 20 years who had or were expected to have TZP-susceptible pathogens, were enrolled in six university-affiliated hospitals in Korea. The study protocol and informed consent form were approved by the Institutional Review Board of each of the six hospitals that enrolled the study patients. Written informed consent was obtained before enrollment in this study. The following exclusion criteria were used: history of hypersensitivity to beta-lactams; use of drugs known to interact with piperacillin or tazobactam such as vecuronium, heparin, warfarin, methotrexate, and probenecid; and aspartate aminotransferase or alanine aminotransferase exceeding three times the upper limit of the normal range.

2. Study design and dosage regimen

At least four consecutive 2/0.25 g or 4/0.5 g doses of TZP were intravenously infused over 1 h every 8 h to patients with creatinine clearance ≤50 mL/min or creatinine clearance > 50mL/min, respectively. Creatinine clearance (CLcr) was calculated using the Cockcroft-Gault formula.

Blood samples from patients at a steady-state were taken pre-dose and at 0 min (immediate), 30 min, and 4-6 h after the fourth infusion. All blood samples were drawn in heparinized tubes, and samples were placed on ice for 0.5-1 h until centrifugation. The plasma samples obtained were separated, promptly aliquoted, and stored at -70°C.

3. Bioanalysis

Concentrations of piperacillin and tazobactam were analyzed using validated liquid chromatography–tandem mass spectrometry (LC–MS/MS), Agilent 1,100 series LC system (Agilent, Wilmington, DE, USA). Piperacillin, tazobactam, and their internal standard (doripenem) were prepared by protein precipitation with 60% acetonitrile. Detection and quantification were performed using a triple quadrupole tandem mass spectrometer with an electrospray ionization interface in the positive and multiple-reaction-monitoring modes. Chromatographic separation of the compounds was accomplished using an Atlantis HILIC column (50 × 2.1 mm, 3 µm; Waters, Milford, MA, USA) with an isocratic elution.

A full validation of the assay was carried out with respect to selectivity, accuracy, precision, recovery, calibration curve, and stability. The calibration curves for piperacillin and tazobactam were linear over ranges of 2.0–500.0 µg/mL and 0.2–
50.0 µg/mL, respectively, with coefficients of determination (R²) greater than 0.995 for all.

4. Pharmacokinetic evaluations

PK analysis with a mixed-effects method was performed using NONMEM software (version 7.3; Icon Development Solutions, Ellicott City, MD, USA), employing a first-order conditional estimation with an interaction method throughout the entire modeling process. Model evaluation and selection were based on graphical and statistical methods. Likelihood ratio test results were considered statistically significant if the objective function value (OFV) of nested models decreased more than 3.84 points (chi-square distribution, degree of freedom = 1). Both one- and two-compartment models were tested for the PK model, and linear (first-order) and non-linear (Michaelis-Menten) elimination were investigated. The inter-individual variability of each parameter was described using a log-normal variance model. Additive, proportional, and combined error models were tested to describe residual error. All population pharmacokinetic model processes were equally applied for piperacillin and tazobactam.

Demographic and clinical characteristics such as age, sex, body weight, creatinine clearance using Cockroft-Gault equations (CLcr), blood urea nitrogen, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and Glasgow Coma Scale (GCS) score were screened as candidate covariates for linear, exponential, and power models. The covariate screening process was performed using visual (parameter versus variable scatterplots/matrix plots) and numerical covariate searching steps. V1 (volume of central compartment) was adjusted for median body weight a priori with a linear relationship to body weight of 60 kg with a linear relationship. The V1 (volume of central compartment) was adjusted for median body weight a priori with a linear relationship to body weight of 60 kg with a linear relationship. The CLcr was selected as a covariate on CL (clearance of central compartment) with a linear relationship to CL. The CLcr, ranged from 14.45 to 146.01 mL/min, on CL significantly reduced the objective function value (OFV 10.387 decreased) and improved the goodness of fit (GOF). No trends that suggested misspecification in the final model were identified in the GOF plots (Fig. 1). Therefore, the final model was as follows:

\[
CL (L/h) = 2.9 + 4.03 \times CLcr / 47, V1 (L) = 19.5 \times weight / 60
\]

Table 1. Demographics of study subjects

| Demographic parameters | Sex (male / female) | Age (years) | Body weight (kg) | Creatinine (mg/dL) | Creatinine clearance (mL/min) | APACHE II score | GCS score | Site of infection |
|------------------------|---------------------|-------------|------------------|--------------------|-------------------------------|-----------------|-----------|------------------|
|                        | 17 (51.5%) / 16 (48.5%) | 68.79 ± 10.97 (46, 88) | 58.17 ± 10.08 (36.30, 75.40) | 1.18 ± 0.80 (0.34, 4.70) | 61.27 ± 36.67 (14.45, 146.01) | 13.48 ± 8.48 (3, 38) | 13.09 ± 2.88 (7, 15) |
|                        |                     |             |                  |                    |                               |                 |           | Lungs            |
|                        |                     |             |                  |                    |                               |                 |           | 13               |
|                        |                     |             |                  |                    |                               |                 |           | Urinary tract    |
|                        |                     |             |                  |                    |                               |                 |           | 12               |
|                        |                     |             |                  |                    |                               |                 |           | Soft tissue      |
|                        |                     |             |                  |                    |                               |                 |           | 6                |
|                        |                     |             |                  |                    |                               |                 |           | Bloodstream      |
|                        |                     |             |                  |                    |                               |                 |           | 2                |
|                        |                     |             |                  |                    |                               |                 |           | Dose (4.5 g / 2.25 g) | 19 (57.6%) / 14 (42.4%) |

Mean ± SD (range) for continuous data and number of the subject (%) for categorical data. APACHE II, acute physiology and chronic health evaluation II; GCS, Glasgow coma scale.
Final PK parameter estimates with corresponding relative standard error values and results of the non-parametric bootstrap are summarized in Table 2. VPC plots in Figure 2 demonstrated that individual predicted tazobactam concentrations concurred with the observed concentrations without systemic bias.

**Discussion**

In the present study, we evaluated the population pharmacokinetic analysis of TZP in Korean patients with acute infections. Our results suggested that both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination, and \( CL_{cr} \) on \( CL \) was a significant covariate for both piperacillin and tazobactam. Notably, clearance of piperacillin in Korean patients is expected to be lower than that in Caucasians in both normal and lower renal function within the normal body weight range. The proposed equation to estimate \( CL \) of piperacillin in Korean patients in this study differed from an equation developed in Caucasians, \((1.29 \times CL_{cr} + 100) \times 60/1,000\) (CPL Associates, personal contact). The results suggested that optimized dosing of TZP of Korean patients might be different from that in Caucasians, because of the low \( CL \) in Korean patients. We believe that further studies should be performed to validate the individualized dosing of TZP to attain a pharmacokinetic or pharmacodynamic targets in Korean patients.

Individualization and optimization of antibiotic dosing regimens, which become gradually achievable using pharmacokinetics, are particularly important in commonly used antimicrobial agents such as piperacillin and tazobactam [17]. Ethnic differences in the pharmacokinetics of various drugs are widely understood, and it is possible that optimization of piperacillin dosing may be influenced by individual characteristics of different races. However, a paucity of data regard-
ing ethnic differences in pharmacokinetics of piperacillin and tazobactam is available, despite several reports of the population pharmacokinetics of piperacillin and tazobactam [18]. We posit that our present study implies that lower clearances of piperacillin and tazobactam in Korean patients with either normal or lower renal function, compared that with Caucasians, could enhance the chance of attaining a pharmacokinetic or pharmacodynamic target, even with smaller dosing of piperacillin and tazobactam. The difference in body weight and composition between Korean and Caucasian patients may affect this result, which is supported by results obtained from previous studies that reveal the impact of body composition and body size on pharmacokinetics between different races [19, 20]. In addition, two recent studies showing that the pharmacokinetics of piperacillin and tazobactam was altered by physiological processes associated with obesity support these results [21, 22]. However, further studies to determine conclusive explanations for these differences are needed.

There is considerable evidence that efficacy of TZP is influenced by appropriate dosing and mode of administration, as well as the minimal inhibitory concentration of piperacillin [8, 9, 17, 23]. However, care should be taken to interpret the results, because most of the previous pharmacokinetic studies did not consider the potential impact of dosage regimens on ethnic differences. It would be ideal to calculate the appropriate dose of TZP to achieve the maximized probability of target attainment using stimulation techniques, which could provide individualized dosing regimens and enable an accurate inter-race comparison. In addition, previously reported toxicity of piperacillin associated with impaired renal function should be compared between ethnic groups, because categorizing dosing by the degree of crude renal function may to be too high or low for patients in the same category, according to race [24, 25].

This study has the following limitations. First, it is a preliminary study to determine the characteristics of piperacillin and tazobactam pharmacokinetics in Korean patients without an efficacy evaluation and validation of dosage regimens. To investigate the ethnic variability, we should calculate the probability of target attainment using population pharmacokinetics in combination with Monte Carlo simulations. Second, the number of patients analyzed in our study was too small to be conclusive and to effectively evaluate the different $CL$ of TZP between races. Therefore, we plan to enroll sufficient patients to confirm and validate individualized dosing of TZP by analyzing clinical outcomes of patients treated with antibiotics.

### Table 2. Final estimates of pharmacokinetic parameters for piperacillin and tazobactam

| Parameter (units) | Estimates | % RSE$^a$ | Bootstrap median (95% CI)$^b$ | Estimates | % RSE$^a$ | Bootstrap median (95% CI)$^b$ |
|------------------|-----------|-----------|-------------------------------|-----------|-----------|-------------------------------|
| Structural model |           |           |                               |           |           |                               |
| TV $CL = \theta_1 + \theta_5 \times CLcr/47$ |           |           |                               |           |           |                               |
| $\theta_1$      | 2.90      | 42.41     | 2.80 (0.01, 5.26)             | 1.76      | 51.28     | 1.72 (0.01, 3.67)             |
| $\theta_5$      | 4.03      | 32.75     | 3.99 (1.82, 7.89)             | 4.81      | 23.49     | 4.79 (2.86, 7.71)             |
| TV $V_1 = \theta_1 \times weight/60$ |           |           |                               |           |           |                               |
| $\theta_1$      | 19.50     | 14.82     | 19.31 (15.15, 29.62)          | 22.6      | 10.84     | 24.10 (20.06, 30.79)          |
| $Q$              | 2.29      | -         | -                             | 1.18      | -         | -                             |
| $V_1$            | 3.76      | -         | -                             | 4.3       | -         | -                             |
| Random variability (CV, %) |           |           |                               |           |           |                               |
| $\omega CL$, interindividual variability of $CL$ | 0.279     | 24.73     | 0.265 (0.146, 0.613)          | 0.211     | 28.67     | 0.198 (0.099, 0.500)          |
| $\omega V_1$, interindividual variability of $V_1$ | 0.179     | 84.36     | 0.177 (0.001, 0.722)          | 0.151     | 68.87     | 0.134 (0.001, 0.418)          |
| Residual variability (%) | 0.399     | 10.78%    | 0.390 (0.297, 0.472)          | 0.393     | 12.26%    | 0.387 (0.297, 0.479)          |

$^a$Relative standard error.

$^b$2.5-97.5 percentile estimated by applying final pharmacokinetic model to 1,000 non-parametric resampled data sets.

CI, confidence interval; $CL$, clearance; $Q$, intercompartmental clearance; $V_1$, volume of central compartment; $V_2$, volume of peripheral compartment; CV, coefficient of variation.
from the established equation for drug CL in Korean patients, as well as Monte Carlo simulations.

In conclusion, the PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by two-compartment models with first-order elimination. Clearances of both piperacillin and tazobactam were significantly influenced by creatinine clearance. This model should be validated for the individualized dosing of TZP to attain a pharmacokinetic target in a large number of patients.

Conflicts of Interest
The study drug was provided by the Kuhnil Pharmaceutical Company.

Funding
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [grant number: A120843-1211-0000600].

Acknowledgements
The authors would like to thank Yun-Jung Yoon from the Pharmacogenomics Research Center, Inje University Busan Paik Hospital, Busan, Korea for her contributions to the analysis of drug concentrations. We would also like to thank to Dr. Jerome J. Schentag, a professor of Pharmaceutical Sciences and Pharmacy at the University at Buffalo, State University of New York, USA, for providing the proposed equation to estimate CL of piperacillin in Korean patients in this study compared with an equation developed in Caucasians.

ORCID
Yong Kyun Kim  http://orcid.org/0000-0002-7935-6952
Jin Ah Jung  http://orcid.org/0000-0003-2439-377X
Sungmin Kiem  http://orcid.org/0000-0003-3518-966X

References
1. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanet GG. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 2007;5:365-83.
2. Maltezou HC, Nikolaides P, Lebesii E, Dimitriou L, Androulakakis E, and Kafetzis DA. Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2001;20:643-6.
3. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987-94.
4. Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M, Delgado A, Horcajada JP, Montero M, Roiz MP, Farinas MC, Alonso J, Martinez LM, Gutiérrez-Macias A, Alava...
JA, Rodriguez A, Fleites A, Navarro V, Sirvent E, Capdevila JA; SEMI-BLEE STUDY GROUP. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp bacteremia. A multicentric cohort study. BMC Infect Dis 2012;12:245.

5. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.

6. Mckinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cephepine and ceftazidine in serious bacterial infections. Int J Antimicrob Agents 2008;31:345-51.

7. Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamics concepts into clinical practice: focus on β-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:1320-32.

8. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010;54:460-5.

9. Dullhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Patterson DL, Lipman J. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013;56:236-44.

10. Roberts JA, Uldemolins M, Roberts MS, McWhinney BC, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332-9.

11. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997;86:1328-33.

12. Chen ML. Ethnic or racial differences revisited: impact of dose regimen form on pharmacokinetics and pharmacodynamics. Clin Pharmacokin 2006;45:957-64.

13. Jeon S, Han S, Lee J, Hong T, Paek J, Woo H, Yim DS. Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother 2014;58:3744-51.

14. Oh KH, Kim C, Lee H, Lee H, Jung JY, Kim NJ, Yu KS, Shin KH, Jang II, Ahn C. Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodialfiltration. Antimicrob Agents Chemother 2009;53:3266-8.

15. Kiem S, Ryu SM, Lee YM, Schentag JJ, Kim YW, Kim HK, Jang HJ, Joo YD, Jin K, Shin JG, Ghim JL. Population pharmacokinetics of levofloxacin in Korean patients. J Chemoth 2016;28:308-13.

16. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-95.

17. Felton TW, Roberts JA, Lodise TP, Guilder MV, Boselli E, Neely MN, Hope WW. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Anmicrob Agents Chemother 2014;58:4094-102.

18. Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetics evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010;6:1017-31.

19. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39:215-31.

20. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994;26:292-307.

21. Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013;41:52-6.

22. Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. J Clin Pharmacol 2015;55:899-908.

23. Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis 2012;55:799-806.

24. Karino F, Nishimura N, Ishihara N, Moriyama H, Miura K, Hamaguchi S, Sutani A, Kuraki T, Morikawa N. Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia. Biol Pharm Bull 2014;37:1971-6.

25. Huang WT, Hsu YJ, Chu PL, Lin SH. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009;37:374-6.